ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 1520 • ACR Convergence 2020

    Characterisation of Rheumatoid and Psoriatic Arthritis Synovial Fibroblasts

    Clare Cunningham1, Sharon Ansboro1, Sarah Wade1, Candice Low2, Ronan Mullan3, Douglas Veale4 and Ursula Fearon5, 1Trinity College Dublin, Dublin, Ireland, 2EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, 3Adelaide and Meath Hospital, Dublin, Dublin, Ireland, 4EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, 5Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland

    Background/Purpose: The synovial inflammation observed in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) is characterised by synovial fibroblast hyperplasia, leukocyte infiltration, neoangiogenesis and hypoxia. These…
  • Abstract Number: 1869 • ACR Convergence 2020

    “Rheum to Diagnosis”: Uncovering Impediments to Accurate Diagnosis of Non-radiographic Axial Spondylarthritis (nr-axSpA)

    Sonam Kiwalkar1, Atul Deodhar1 and Richard Howard2, 1Oregon Health & Science University, Portland, OR, 2Spondylitis Association of America, Van Nuys, CA

    Background/Purpose: In the US, there is up to a 14-year delay in axSpA diagnosis, which is likely greater for nr-axSpA.1 Impediments to timely diagnosis of…
  • Abstract Number: 0120 • ACR Convergence 2020

    Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases

    Giovanni Adami1, Angelo Fassio2, Alessandro Giollo2, Luca Idolazzi2, Ombretta Viapiana1, Davide Gatti2 and Maurizio Rossini2, 1University of Verona, Verona, Italy, 2Rheumatology Unit, University of Verona, Verona, Italy

    Background/Purpose: The aim of the present work is to determine the fracture risk associated with glucocorticoids requiring diseasesMethods: We conducted a retrospective analysis of a nation-wide…
  • Abstract Number: 0645 • ACR Convergence 2020

    Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis

    Anne-Claire Desbois1, Cindy Marques1, Leila Lefèvre1, Serge Barmo1, Camille Lorenzo1, Mathilde Leclercq1, Gaëlle Leroux1, Chloé Comarmond1, Catherine Chapelon-Abric1, Fanny Domont1, David Saadoun1 and Patrice Cacoub1, 1AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Paris, France

    Background/Purpose: To investigate the prevalence, clinical features and outcomes of coronavirus disease 2019 (COVID-19) among sarcoidosis patients.Methods: We retrospectively collected clinical features, treatments and outcomes…
  • Abstract Number: 0845 • ACR Convergence 2020

    Hematopoietic Specific Deficiency of Rho Kinase Attenuates Neutrophil NETosis and UVB-induced Skin Inflammation

    Minghui Li1, Xing Lyu1, Yubin Li2, James Liao3, Victoria Werth4 and Ming-Lin Liu1, 1University of Pennsylvania, philadelphia, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 3University of Chicago, Chicago, 4University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia

    Background/Purpose: Neutrophils are the most abundant leukocytes and the first to be recruited to the site of photodamage after ultraviolet B (UVB) exposure. We have…
  • Abstract Number: 1188 • ACR Convergence 2020

    Serum Anti-malondialdehyde-acetaldehyde IgA Antibody Concentration Improves Prediction of Coronary Atherosclerosis Beyond Traditional Risk Factors in Patients with Rheumatoid Arthritis

    Hannah Lomzenski1, Geoffrey Thiele2, Michael Duryee2, Sheau-Chiann Chen1, Fei Ye1, Ted Mikuls2, C. Michael Stein1 and Michelle Ormseth1, 1Vanderbilt University Medical Center, Nashville, TN, 2University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Patients with rheumatoid arthritis (RA) have increased cardiovascular disease (CVD) independent of traditional risk factors. Oxidative stress is increased in patients with RA and…
  • Abstract Number: 1530 • ACR Convergence 2020

    Activin a and Follistatin Alter Endothelial Cell and Rheumatoid Arthritis Synovial Fibroblast Adhesion and Interaction

    Helge Scholz1, Iris Aykara1, Klaus Frommer2, Stefan Rehart3, Ulf Müller-Ladner4 and Elena Neumann1, 1Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany, 2Justus-Liebig-University Giessen, Campus Kerckhoff, Dept. of Rheumatology and Clinical Immunology, Bad Nauheim, Germany, 3Department of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital, Frankfurt, Frankfurt, Germany, 4Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany

    Background/Purpose: Activin A and follistatin belong to an anti-inflammatory auto-regulatory cycle. Patients with rheumatoid arthritis (RA) have increased activin A levels in the synovial fluid…
  • Abstract Number: 1904 • ACR Convergence 2020

    Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis

    Xenofon Baraliakos1, Rebecca Bolce2, David Sandoval2, Soyi Liu-Leage3, Vladimir Geneus3, David Adams3, Atul Deodhar4, Jessica Walsh5 and Joachim Sieper6, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 2Eli Lilly and Company, Indianapolis, 3Eli Lilly and Company, Indianapolis, IN, 4Oregon Health & Science University, Portland, OR, 5University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, 6Charité Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Biologic therapy is recommended in patients with active ankylosing spondylitis (AS) despite adequate trial of NSAIDs. Biologic treatment in AS are currently limited to…
  • Abstract Number: 0290 • ACR Convergence 2020

    Role of Protein Tyrosine Phosphatase 1B (PTP1B) in Endothelial-to-Mesenchymal Transition (EndoMT) Promoted by Inflammation: Implications for SLE

    Jorge Romo-Tena1, José Esparza-López2, Carmelo Carmona-Rivera3, Luz Blanco4, Mariana Kaplan3 and María de Jesús Ibarra-Sánchez2, 1NIAMS, National Institute of Health, Bethesda, 2INNSZ / UNAM-RAI, Mexico City, Mexico, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville

    Background/Purpose: The endothelial-to-mesenchymal transition (EndoMT) transdifferentiation process can be promoted by several proinflammatory mediators in many pathological conditions. Recently, it was suggested a crucial role…
  • Abstract Number: 0650 • ACR Convergence 2020

    Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout

    Marco Ferrández-Jiménez1, Irene Calabuig2, Maria Luisa Peral2, Miguel Gómez-Garberí1 and Mariano Andrés2, 1Universidad Miguel Hernández de Elche, Alicante, Spain, 2Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain

    Background/Purpose: Osteoporosis causes significant morbidity and mortality through the development of fragility fractures, including vertebral fractures (VF). Patients with gout may show an increased risk…
  • Abstract Number: 0885 • ACR Convergence 2020

    Impact of HLA-B27 Status on Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Secukinumab

    Atul Deodhar1, Philip Mease2, Denis Poddubnyy3, Vibeke Strand4, Paula Machado5, Abhijit Shete6, Xiangyi Meng5 and Marina Magrey7, 1Oregon Health & Science University, Portland, OR, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Charité – Universitätsmedizin Berlin, Berlin, Germany, 4Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Novartis Pharma AG, Basel, Switzerland, 7Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Ankylosing spondylitis (AS) is strongly associated with the genetic marker HLA-B27. In patients with AS, negative HLA-B27 status is a predictor of worse response…
  • Abstract Number: 1191 • ACR Convergence 2020

    Specificity for Inflammatory Pathways Associated with Coronary Microvascular Dysfunction in Rheumatoid Arthritis

    Brittany Weber1, Zeling He1, Sicong Huang1, Daniel H. Solomon2, Elena Massarotti1, Charlotte Golnik1, Thany Seyok1, Seth Brownmiller1, Laurel Martell1, Leann Barrett1, Courtney Bibbo1, Marcy Bolster3, Marcelo DiCarli1 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Concord, MA

    Background/Purpose: Coronary microvascular disease (CMD) is associated with increased mortality in RA independent of traditional cardiovascular (CV) risk factors. Inflammation likely plays an important role…
  • Abstract Number: 1544 • ACR Convergence 2020

    Tc99m Tilmanocept Imaging Is an Early Predictor of Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy

    Mara Leach1, David Ralph1, Beth Potter1, Bonnie Abbruzzese1, Rachael Hershey1, Jessica Fitzpatrick1, Katherine Repp1, Haya Shakhtra1, Madison Palmer1, Nicole Korczak1, Audrey Villarosa1, Michael Blue1, Martin Jacobs2, Yelliann Ruis3, Debbie Foley4, Alan Kivitz5 and Michael Rosol1, 1Navidea Biopharmaceuticals, Dublin, 2Kettering Medical Center, Kettering, 3Innovation Medical Research Center, Palmetto Bay, 4Premier Rheumatology of Oklahoma, Tulsa, 5Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA

    Background/Purpose: Rheumatoid Arthritis (RA) is a serious and potentially debilitating disease, but low disease activity and even clinical remission can be obtained if an effective…
  • Abstract Number: 1931 • ACR Convergence 2020

    Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis

    Naomi Serling-Boyd1, Xiaoqing Fu2, Yuqing Zhang3, Sebastian Unizony1, Zachary Wallace4, Hyon Choi5 and John H. Stone6, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital, Newton, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, 6Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Giant cell arteritis (GCA) is a form of large vessel vasculitis that requires treatment with high-dose, long-term glucocorticoids (GC). Weight gain, among other side-effects…
  • Abstract Number: 0300 • ACR Convergence 2020

    Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin

    Sirisha Sirobhushanam1, Allison Billi2, Alex Tsoi2, Celine Berthier2, Johann Gudjonsson3 and J. Michelle Kahlenberg4, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, 3University of Michigan, Ann ArborUniversity of Michigan, 4Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 58
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology